Cidara Therapeutics price target raised to $110 from $74 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cidara Therapeutics (CDTX) to $110 from $74 and keeps a Buy rating on the shares after the company announced that the first patients have been in dosed in its registrational Phase 3 ANCHOR study evaluating CD388 for the prevention of seasonal influenza. With the expanded patient population, which brings the initial addressable target population from 50M to over 100M in the U.S. alone, the market opportunity for CD388 continues to strengthen, the analyst tells investors in a research note.